HEALIONICS CORPORATION — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to eva
HEALIONICS CORPORATION — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $224,499
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- WA
- Period
- —
Description
DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to evaluate a novel vascular graft design for use as the arteriovenous (AV) graft component of a new needle-free access port. Significance: Hemodialysis patients require painful punctures with large needles for vascular access on a near-daily basis. This worsens quality of life, and the repeated tissue trauma makes maintenance of a reliable long-term access difficult. AV grafts (the safest option for the 40% of patients unable to sustain an autogenous fistula) are prone to thrombosis at the venous anastomosis and other needle-trauma-related complications such as infection and hematoma. A device that could circumvent the issues associated with needlesticks and provide patient-friendly long-term vascular access with low complication rate would have major impact. Innovation: STARport is a new percutaneous hemodialysis port under development that provides blunt cannula access to the inside of an AV graft. It uses Healionics'